Drug intelligence / Profile preview

KINE-401A

Development stage: Preclinical
Lead developer: Kine Sciences
Modality: Peptides

Overview

KINE-401A is a peptide-based cancer immunotherapy candidate currently in the discovery stage, developed by Kine Science. It is designed to target and activate Natural Killer (NK) cells to enhance their anti-tumor effector functions against solid tumors. By modulating NK cell activity, KINE-401A aims to leverage the innate immune system to identify and eliminate malignant cells within the tumor microenvironment, potentially overcoming mechanisms of immune evasion. As a peptide modality, it represents a targeted approach to immunotherapy distinct from traditional monoclonal antibodies or cell-based therapies.

Beyond the preview

Go deeper on KINE-401A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KINE-401A.

Explore the full profile